Analyst Price Target is $28.83
▲ +460.96% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Caribou Biosciences in the last 3 months. The average price target is $28.83, with a high forecast of $37.00 and a low forecast of $19.00. The average price target represents a 460.96% upside from the last price of $5.14.
Current Consensus is
Buy
The current consensus among 4 investment analysts is to buy stock in Caribou Biosciences.
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for the treatment of solid tumors. It has collaboration with AbbVie Manufacturing Management Unlimited Company to develop CAR-T cell therapies. The company was incorporated in 2011 and is headquartered in Berkeley, California.
Read More
